2.9401
price up icon1.38%   0.0401
 
loading
前日終値:
$2.90
開ける:
$2.95
24時間の取引高:
3,497
Relative Volume:
0.00
時価総額:
$10.75M
収益:
-
当期純損益:
$-60.61M
株価収益率:
-3.2668
EPS:
-0.9
ネットキャッシュフロー:
$-22.91M
1週間 パフォーマンス:
+4.25%
1か月 パフォーマンス:
-17.88%
6か月 パフォーマンス:
+553.04%
1年 パフォーマンス:
+334.20%
1日の値動き範囲:
Value
$2.8541
$2.95
1週間の範囲:
Value
$2.7363
$2.9507
52週間の値動き範囲:
Value
$0.0815
$4.44

Bioline Rx Ltd Adr Stock (BLRX) Company Profile

Name
名前
Bioline Rx Ltd Adr
Name
セクター
Healthcare (1155)
Name
電話
-
Name
住所
-
Name
職員
28
Name
Twitter
Name
次回の収益日
2025-03-26
Name
最新のSEC提出書
Name
BLRX's Discussions on Twitter

BLRX を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
BLRX
Bioline Rx Ltd Adr
2.9401 10.75M 0 -60.61M -22.91M -0.90
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
490.46 127.47B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
577.23 62.43B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
599.32 37.03B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
232.66 31.06B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
249.43 26.16B 3.81B -644.79M -669.77M -6.24

Bioline Rx Ltd Adr Stock (BLRX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2017-05-18 アップグレード Maxim Group Hold → Buy
2017-02-13 開始されました Rodman & Renshaw Buy
2016-08-12 ダウングレード Maxim Group Buy → Hold
2015-08-17 繰り返されました Maxim Group Buy
2015-07-27 繰り返されました ROTH Capital Buy
2015-06-22 開始されました JMP Securities Mkt Outperform
すべてを表示

Bioline Rx Ltd Adr (BLRX) 最新ニュース

pulisher
Apr 01, 2025

BioLineRx stock rating cut to Hold at Jones Trading - Investing.com

Apr 01, 2025
pulisher
Apr 01, 2025

BLRX stock touches 52-week low at $2.85 amid sharp annual decline - Investing.com

Apr 01, 2025
pulisher
Apr 01, 2025

H.C. Wainwright raises BioLineRx stock target to $26 - Investing.com India

Apr 01, 2025
pulisher
Apr 01, 2025

BioLineRx Ltd. Reports 2024 Financial Results and Strategic Progress - TipRanks

Apr 01, 2025
pulisher
Mar 31, 2025

BioLineRx Earnings Call: Strategic Shifts and Growth - TipRanks

Mar 31, 2025
pulisher
Mar 31, 2025

BioLineRx price target adjusted to $26 at H.C. Wainwright after reverse split - TipRanks

Mar 31, 2025
pulisher
Mar 31, 2025

Options Volatility and Implied Earnings Moves This Week, March 31 – April 03, 2025 - The Globe and Mail

Mar 31, 2025
pulisher
Mar 31, 2025

BioLineRx Reports Strong 2024 Financial Results and Strategic Advancements - TipRanks

Mar 31, 2025
pulisher
Mar 07, 2025

Bioline RX Ltd Sponsored ADR to Host Earnings Call - ACCESS Newswire

Mar 07, 2025
pulisher
Feb 27, 2025

Investor Network: Bioline RX Ltd Sponsored ADR to Host Earnings Call - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 19, 2025

BLRX: Aphexda Transition Progressing - Research Tree

Feb 19, 2025
pulisher
Jan 31, 2025

BioLineRx stock hits 52-week low at $3.24 amid sharp decline - Investing.com India

Jan 31, 2025
pulisher
Jan 21, 2025

BioLineRx announces strategic shift with licensing deals - Investing.com

Jan 21, 2025
pulisher
Jan 21, 2025

BioLineRx Outlines Strategic Vision and Financial Outlook After Key Licensing Deals - TipRanks

Jan 21, 2025
pulisher
Jan 17, 2025

BioLineRx Adjusts ADS Ratio to Maintain Nasdaq Listing - TipRanks

Jan 17, 2025
pulisher
Jan 17, 2025

BioLineRx Announces 1:40 ADS Ratio Change, Confirms $29.5M Cash Runway Through 2026 - Stock Titan

Jan 17, 2025
pulisher
Jan 13, 2025

BioLineRx stock touches 52-week low at $0.14 amid downturn - Investing.com India

Jan 13, 2025
pulisher
Jan 13, 2025

BioLineRx stock touches 52-week low at $0.14 amid downturn By Investing.com - Investing.com South Africa

Jan 13, 2025
pulisher
Jan 07, 2025

BiolineRx Announces Major Direct Offering to Bolster Operations - TipRanks

Jan 07, 2025
pulisher
Jan 06, 2025

BioLineRx stock plunges to 52-week low of $0.19 amid market challenges - Investing.com

Jan 06, 2025
pulisher
Jan 06, 2025

BioLineRx Announces $10 Million Direct Offering to Fuel Growth - TipRanks

Jan 06, 2025
pulisher
Dec 16, 2024

BioLineRx stock hits 52-week low at $0.21 amid market challenges - Investing.com

Dec 16, 2024
pulisher
Dec 06, 2024

BioLineRx stock plunges to 52-week low, hits $0.25 - Investing.com India

Dec 06, 2024
pulisher
Nov 26, 2024

BioLineRx stock target cut, retains buy on Q3 financial results - Investing.com

Nov 26, 2024
pulisher
Nov 25, 2024

BioLineRx Reports Strategic Moves in Q3 2024 - TipRanks

Nov 25, 2024
pulisher
Nov 25, 2024

BioLineRx earnings beat by $0.04, revenue topped estimates By Investing.com - Investing.com South Africa

Nov 25, 2024
pulisher
Nov 25, 2024

BioLineRx earnings beat by $0.04, revenue topped estimates - Investing.com India

Nov 25, 2024
pulisher
Nov 25, 2024

Earnings call: BioLineRx announces Q3 results and strategic shifts - Investing.com

Nov 25, 2024
pulisher
Nov 25, 2024

Earnings call: BioLineRx announces Q3 results and strategic shifts By Investing.com - Investing.com South Africa

Nov 25, 2024
pulisher
Nov 25, 2024

BioLineRx Secures Key Deals to Boost Shareholder Value - TipRanks

Nov 25, 2024
pulisher
Nov 25, 2024

IO Biotech Inc (NASDAQ: IOBT) Is A Buzzing Hot Stock - Stocks Register

Nov 25, 2024
pulisher
Nov 25, 2024

Options Volatility and Implied Earnings Moves Today, November 25, 2024 - TipRanks

Nov 25, 2024
pulisher
Nov 22, 2024

BioLineRx, Ayrmid enter license agreement for motixafortide through Gamida Cell - Yahoo Finance

Nov 22, 2024
pulisher
Nov 21, 2024

BioLineRx stock hits 52-week low at $0.38 amid market challenges - Investing.com

Nov 21, 2024
pulisher
Nov 21, 2024

BiolineRx Ltd. Announces New Direct Offering of Shares - TipRanks

Nov 21, 2024
pulisher
Nov 21, 2024

SEC Form 424B5 filed by BioLineRx Ltd. - Quantisnow

Nov 21, 2024
pulisher
Nov 20, 2024

BioLineRx to Report Third Quarter 2024 Results on November 25, 2024 - Benzinga

Nov 20, 2024
pulisher
Nov 20, 2024

BioLineRx to Report Q3 2024 Financial Results on November 25 - StockTitan

Nov 20, 2024
pulisher
Nov 12, 2024

BioLineRx Granted Extension to Meet Nasdaq Requirements - TipRanks

Nov 12, 2024
pulisher
Nov 05, 2024

BioLineRx’s Motixafortide Shows Promise in Sickle Cell Trials - TipRanks

Nov 05, 2024
pulisher
Oct 24, 2024

BioLineRx stock hits 52-week low at $0.39 amid market challenges - Investing.com India

Oct 24, 2024
pulisher
Oct 16, 2024

BioLineRx Secures Extended U.S. Patent for Motixafortide - TipRanks

Oct 16, 2024
pulisher
Oct 16, 2024

BioLineRx secures US patent for cancer drug motixafortide - Investing.com

Oct 16, 2024
pulisher
Oct 16, 2024

BioLineRx secures US patent for cancer drug motixafortide By Investing.com - Investing.com UK

Oct 16, 2024
pulisher
Oct 15, 2024

BioLineRx stock hits 52-week low at $0.43 amid market challenges - Investing.com

Oct 15, 2024
pulisher
Oct 02, 2024

BioLineRx stock hits 52-week low at $0.5 amid market challenges - Investing.com

Oct 02, 2024
pulisher
Oct 01, 2024

BioLineRx Ltd. Shareholders Approve Key Resolutions - TipRanks

Oct 01, 2024

Bioline Rx Ltd Adr (BLRX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$19.80
price down icon 1.75%
$70.30
price up icon 2.22%
$32.51
price up icon 0.87%
$26.24
price up icon 1.84%
$102.53
price down icon 0.01%
biotechnology ONC
$248.35
price up icon 8.46%
大文字化:     |  ボリューム (24 時間):